Compounds > emitefur
Page last updated: 2024-11-06

emitefur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Emitefur: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65910
CHEMBL ID2104592
SCHEMBL ID27921
MeSH IDM0361104

Synonyms (31)

Synonym
last-f
emitefur
bof-a2
m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile benzoate (ester)
benzoic acid, 3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester
benzoic acid, 3-((3-(etoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester
ccris 6984
emitefur [inn]
3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil
3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxymethyl-5- fluorouracil
3-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester
m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate
110690-43-2
emitefur (usan/inn)
D03987
(6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate
unii-9i50nf4aq2
emitefur [usan:inn]
9i50nf4aq2 ,
CHEMBL2104592
AKOS016014066
FT-0631052
SCHEMBL27921
emitefur [jan]
emitefur [usan]
emitefur [mi]
DTXSID80149360
lastf
6-(benzoyloxy)-3-cyanopyridin-2-yl 3-(3-(ethoxymethyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-1-carbonyl)benzoate
3-[3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-ethoxymethyl-5-fluorouracil
Q27272578

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"To determine the toxicities, dose-limiting toxicities (DLT), maximum-tolerated dose, and pharmacokinetic profile of emitefur (BOF-A2) in patients with advanced solid tumors."( Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
Corey, A; Eager, R; Hoff, PM; Nemunaitis, J; Pazdur, R; Sekar, K; Thompson, J; Tkaczuk, K; Twaddell, T, 2000)		0.75

Dosage Studied

ExcerptRelevanceReference
"8-30 mg/kg of BOF-A2) was orally administered every day to 5 mice in each dosage group for 4 weeks."( The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma.
Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K, 1999)		0.3
" This variability makes effective dosing of 5-FU and related drugs difficult."( Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio, RB, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (7.41)18.7374
1990's20 (74.07)18.2507
2000's5 (18.52)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.17 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (11.11%)5.53%
Reviews10 (37.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (51.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		1.9710azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		5.8980pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		9.97273nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
oxonic acid
Oxonic Acid: Antagonist of urate oxidase.		5.81601,3,5-triazines;
monocarboxylic acid
tegafur
[no description available]		6.61110organohalogen compound;
pyrimidines
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		1.9810mitomycinalkylating agent;
antineoplastic agent
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		1.9710nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
fluorodeoxyuridylate
Fluorodeoxyuridylate: 5-Fluoro-2'-deoxyuridylate. An inhibitor of thymidylate synthetase. Formed from 5-fluorouracil or 5-fluorodeoxyuridine.		3.0810pyrimidine 2'-deoxyribonucleoside 5'-monophosphate
pyrimidine
pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.		1.9710diazine;
pyrimidines		Daphnia magna metabolite
deoxycytidine
[no description available]		5.4950pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		4.2930delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		420taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
eniluracil
eniluracil: structure in first source; inactivates dihydropyrimidine dehydrogenase		4.6430pyrimidone
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		3.0910organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		4.2930carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		4.6430carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
ro 09-1390
Ro 09-1390: structure given in first source		3.0810
2,6-dihydroxy-3-cyanopyridine
2,6-dihydroxy-3-cyanopyridine: inhibitor of 5-fluorouracil degradation		2.6730
uftoral
UFT(R) drug: a drug containing tegafur and uracil; a biochemical modulator of 5-fluorouracil; used for postoperative chemotherapy of colon cancer; reported to cause severe liver injury; do not confuse with 1-UFT protocol		4.0120
1-ethoxymethyl-5-fluorouracil
[no description available]		2.6730
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		420secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
carboplatin
[no description available]		3.0910
sorivudine
[no description available]		6.9910organic molecular entity
arabinofuranosyluracil
Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.		1.9910
s 1 (combination)
S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer		5.8160
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		5.49505-formyltetrahydrofolic acidantineoplastic agent;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Colorectal Cancer
[description not available]		04.7950
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		04.7950
Adenocarcinoma, Basal Cell
[description not available]		03.7721
Carcinoma, Non-Small Cell Lung
[description not available]		04.9831
Carcinoma, Epidermoid
[description not available]		04.0731
Leukocytopenia
[description not available]		03.7821
Cancer of Lung
[description not available]		05.5461
Thrombopenia
[description not available]		03.3711
Emesis
[description not available]		03.3711
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		03.7721
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		03.3711
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		04.9831
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		04.0731
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		08.7821
Lung Neoplasms
Tumors or cancer of the LUNG.		05.5461
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3711
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		03.3711
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3711
Carcinoma, Large Cell
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)		03.3711
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.940
Cancer of Colon
[description not available]		01.9810
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9810
Reticulum Cell-Like Sarcoma, Yoshida
[description not available]		02.6730
Abnormalities, Autosome
[description not available]		01.9810
Adenocarcinoma, Papillary
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)		01.9810
Benign Neoplasms
[description not available]		0641
Experimental Neoplasms
[description not available]		03.9950
Experimental Mammary Neoplasms
[description not available]		03.320
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		0641
Cancer of Stomach
[description not available]		04.0631
Stomach Neoplasms
Tumors or cancer of the STOMACH.		04.0631
Cancer of Pancreas
[description not available]		03.320
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.320
Carcinoma, Oat Cell
[description not available]		02.910
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		02.910
Cancer of Gastrointestinal Tract
[description not available]		02.9110
Breast Cancer
[description not available]		02.9110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9110
Disease Exacerbation
[description not available]		03.3911
Sarcoma 180
An experimental sarcoma of mice.		02.3720
EHS Tumor
[description not available]		01.9710